HK Stock Connect Insight | JINHAI MED TECH (02225.HK): Minimally invasive surgery revenue rises to 74.7% of total; southbound stake rises to 0.90% after Stock Connect entry on Sept 7
- First-half 2026 revenue reached SGD34.021 million (up 134.2%), with revenue from minimally invasive surgery solutions and medical products at SGD25.427 million (up 301.5%) and its share of total revenue rising to 74.7%, replacing the traditional labour services business as the core revenue source.
- Following Stock Connect inclusion on 7 September, southbound holdings grew from 10.3 million shares (0.18%) on 9 September to about 47.715 million shares (0.90%) on 23 October, with the largest single-day net addition of 7.73 million shares recorded on 11 September.
NewTimeSpace News:Jinhai Medical Technology Limited (02225.HK) has seen a marked improvement in its fundamentals recently. According to the Company's latest disclosed interim results for the six months ended 30 June 2026, reported in Singapore dollars, its strategic focus has substantively shifted towards the high-value-added medical device sector. During the period, the Company recorded revenue of SGD34.021 million, up 134.2% year on year. By segment, revenue from minimally invasive surgical solutions, medical products and related service fees was particularly strong, surging from SGD6.333 million in the same period last year to SGD25.427 million, an increase of 301.5%, and its share of total Group revenue rose to about 74.7%, establishing it as the Group's core business. Driven by the high-margin business, gross profit increased from SGD2.082 million to SGD6.622 million, and the overall gross margin rose from 14.3% to 19.5%. Loss for the period narrowed to SGD3.630 million, compared with a loss of SGD10.800 million in the same period last year, with basic and diluted loss per share of 0.08 Singapore cents. As at end-June, the Group held cash and cash equivalents of SGD18.20 million, borrowings and lease liabilities totalled SGD14.20 million, and the gearing ratio was maintained at a healthy 25.5%.
In the Hong Kong market, the share price of Jinhai Medical Technology has retreated recently on thin turnover. As of the close on 27 October, the shares were pulled up in the closing session to close at HK$3.755, up 0.13%.
On southbound holdings, the company was added to the Stock Connect list effective 7 September 2026. According to Choice data, southbound holdings stood at 10.3 million shares on 9 September, equal to 0.18% of the total share capital, and have continued to increase since then; the largest single-day net addition was 7.73 million shares on 11 September, up to 26 October since inclusion. By 26 October, southbound holdings further rose to 48.23 million shares, or 0.90% of the total, the highest level since inclusion, with a net addition of 515,000 shares on the day.
- ROBOTECHNIK (03757.HK): H shares included in Stock Connect eligible securities list from 26 October
- HK Stock Connect Insight | LONGBIO-B (01779.HK) proposes amendments to the articles of association for review at the EGM on October 30; southbound holding ratio rises to 3.48%
- HK Stock Connect Insight | YUNFENG FIN (00376.HK) proposes sale of Yunfeng Financial Markets to streamline the licensing structure; southbound holding ratio falls to 0.91%
- HK Stock Connect Watch | CREALIGHTS (01191.HK) revises IPO proceeds use to boost raw material purchases; southbound holdings ratio rises to 4.6%
- HK Stock Connect Watch | YUNJI (02670.HK) partners with Taobao Shangou: southbound holdings ratio rises to 1.58%
